Amundi Grows Stake in Moderna, Inc. (NASDAQ:MRNA)

Amundi lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 79.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,206,273 shares of the company’s stock after buying an additional 535,273 shares during the quarter. Amundi’s holdings in Moderna were worth $52,075,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB boosted its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna during the fourth quarter valued at $37,000. Venturi Wealth Management LLC boosted its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MRNA. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $60.63.

Moderna Price Performance

Shares of MRNA stock opened at $35.01 on Thursday. The company has a market capitalization of $13.51 billion, a price-to-earnings ratio of -3.77 and a beta of 1.86. The company’s fifty day moving average price is $36.25 and its 200-day moving average price is $48.01. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.